Daratumumab: a game changer in myeloma therapy
Author:
- 1 June 2020
- journal article
- editorial
- Published by Elsevier in The Lancet Haematology
- Vol. 7 (6) , e426-e427
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trialsThe Lancet Haematology, 2020
- Subcutaneous delivery of daratumumab in relapsed or refractory multiple myelomaBlood, 2019
- Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014‐04 (Etoile du Nord) trialBritish Journal of Haematology, 2019
- Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re‐treatment with daratumumab among refractory patientsCancer, 2019
- Daratumumab in multiple myelomaCancer, 2019
- Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective studyAnnals of Hematology, 2019
- Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myelomaCancer, 2018
- CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of ResistanceFrontiers in Immunology, 2018
- Daratumumab, Bortezomib, and Dexamethasone for Multiple MyelomaNew England Journal of Medicine, 2016
- Targeting CD38 with Daratumumab Monotherapy in Multiple MyelomaNew England Journal of Medicine, 2015